/PRNewswire/ CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces.
Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug application (IND) for AC0176 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
/PRNewswire/ Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to.
/PRNewswire/ Caris Life Sciences® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to.